MDT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

8.89B

+7.22%

1.335

-3.96%

9.63B

+7.87%

1.686

+4.08%

9.06B

+6.08%

1.371

+8.83%

Estimates Revision

The market is revising Upward the revenue expectations for Medtronic plc (MDT) for FY2026, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by 0.99%.

Revenue Estimates for FY2026

Revise Upward

+0.63%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+0.5%

In Past 3 Month

Stock Price

Go Up

+0.99%

In Past 3 Month

21 Analyst Rating

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

11 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

90.00

Averages

110.47

High

119.00

Current: 0.000

Low

90.00

Averages

110.47

High

119.00

Bernstein

Outperform

maintain

$111 -> $112

2026-01-09

New

Reason

Bernstein

Price Target

$111 -> $112

2026-01-09

New

maintain

Outperform

Reason

Bernstein raised the firm's price target on Medtronic to $112 from $111 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Barclays

Matt Miksic

Overweight

maintain

$111 -> $116

2026-01-08

New

Reason

Barclays

Matt Miksic

Price Target

$111 -> $116

2026-01-08

New

maintain

Overweight

Reason

Barclays analyst Matt Miksic raised the firm's price target on Medtronic to $116 from $111 and keeps an Overweight rating on the shares. The firm cites an increased target multiple for the boost to put the stock in line with the recent increase in peers.

William Blair

Brandon Vazquez

Market Perform -> Outperform

upgrade

2026-01-06

New

Reason

William Blair

Brandon Vazquez

Price Target

2026-01-06

New

upgrade

Market Perform -> Outperform

Reason

William Blair analyst Brandon Vazquez upgraded Medtronic to Outperform from Market Perform without a price target as part of its 2026 outlook for the medical technology group. The company has several new and ramping launches this year, the analyst tells investors in a research note. William Blair says volumes and spending budgets "remain solid" in the medtech space with earnings estimates "finally going up." This is a good setup for medtech into 2026, contends the firm.

Truist

Richard Newitter

Hold

downgrade

$110 -> $107

2025-12-18

Reason

Truist

Richard Newitter

Price Target

$110 -> $107

2025-12-18

downgrade

Hold

Reason

Truist analyst Richard Newitter lowered the firm's price target on Medtronic to $107 from $110 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Baird

Neutral

downgrade

$109 -> $103

2025-12-16

Reason

Baird

Price Target

$109 -> $103

2025-12-16

downgrade

Neutral

Reason

Baird lowered the firm's price target on Medtronic to $103 from $109 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Nephron Research

Hold

Buy

upgrade

$120

2025-12-08

Reason

Nephron Research

Price Target

$120

2025-12-08

upgrade

Hold

Buy

Reason

Nephron Research upgraded Medtronic to Buy from Hold with a $120 price target. The firm says the company's pickup in growth "has legs."

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT.N) is 16.41, compared to its 5-year average forward P/E of 17.07. For a more detailed relative valuation and DCF analysis to assess Medtronic PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

17.07

Current PE

16.41

Overvalued PE

19.62

Undervalued PE

14.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.50

Current EV/EBITDA

13.71

Overvalued EV/EBITDA

16.45

Undervalued EV/EBITDA

12.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.78

Current PS

3.33

Overvalued PS

4.51

Undervalued PS

3.06

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 288.1% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 167.88% over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 288.1% over the last month.

Sold

Bought

MDT News & Events

Events Timeline

No data

News

7.0

15:06 PMFool

Pfizer Faces Patent Cliffs, Dismal Outlook for 2026

7.0

15:04 PMNASDAQ.COM

Vertex and Medtronic Show Strong Prospects While Pfizer Faces Challenges

8.5

14:02 PMBenzinga

Haemonetics Acquires Vivasure Medical for €100 Million to Enhance Vascular Access Solutions

People Also Watch

Frequently Asked Questions

What is Medtronic PLC (MDT) stock price today?

The current price of MDT is 97.46 USD — it has decreased -1.25 % in the last trading day.

What is Medtronic PLC (MDT)'s business?

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

What is the price predicton of MDT Stock?

What is Medtronic PLC (MDT)'s revenue for the last quarter?

Medtronic PLC revenue for the last quarter amounts to 8.96B USD, increased 6.64 % YoY.

What is Medtronic PLC (MDT)'s earnings per share (EPS) for the last quarter?

Medtronic PLC. EPS for the last quarter amounts to 1.07 USD, increased 8.08 % YoY.

What changes have occurred in the market's expectations for Medtronic PLC (MDT)'s fundamentals?

How many employees does Medtronic PLC (MDT). have?

Medtronic PLC (MDT) has 95000 emplpoyees as of January 09 2026.

What is Medtronic PLC (MDT) market cap?

Today MDT has the market capitalization of 126.52B USD.